Properties of nonaqueous electrolytes Quarterly report, 20 Dec. 1966 - 19 Mar. 1967

Properties of nonaqueous electrolytes - preparation of electrolytes, nuclear magnetic resonance structural studies, and physical property determination

Properties of nonaqueous electrolytes Quarterly report, 20 Jun. - 19 Sep. 1967

Electrolyte preparation, and physical property and nuclear magnetic resonance structural studies of nonaqueous electrolyte

Properties of nonaqueous electrolytes Sixth summary report, 20 Sep. 1967 - 19 Mar. 1968

Physical properties and structural studies on propylene carbonate, dimethyl formamide, and acetonitrile solvent electrolyte

Enzymatic engineering of the porcine genome with transposons and recombinases

<p>Abstract</p> <p>Background</p> <p>Swine is an important agricultural commodity and biomedical model. Manipulation of the pig genome provides opportunity to improve production efficiency, enhance disease resistance, and add value to swine products. Genetic engineering can also expand the utility of pigs for modeling human disease, developing clinical treatment methodologies, or donating tissues for xenotransplantation. Realizing the full potential of pig genetic engineering requires translation of the complete repertoire of genetic tools currently employed in smaller model organisms to practical use in pigs.</p> <p>Results</p> <p>Application of transposon and recombinase technologies for manipulation of the swine genome requires characterization of their activity in pig cells. We tested four transposon systems- <it>Sleeping Beauty</it>, <it>Tol2</it>, <it>piggyBac</it>, and <it>Passport </it>in cultured porcine cells. Transposons increased the efficiency of DNA integration up to 28-fold above background and provided for precise delivery of 1 to 15 transgenes per cell. Both Cre and Flp recombinase were functional in pig cells as measured by their ability to remove a positive-negative selection cassette from 16 independent clones and over 20 independent genomic locations. We also demonstrated a Cre-dependent genetic switch capable of eliminating an intervening positive-negative selection cassette and activating GFP expression from episomal and genome-resident transposons.</p> <p>Conclusion</p> <p>We have demonstrated for the first time that transposons and recombinases are capable of mobilizing DNA into and out of the porcine genome in a precise and efficient manner. This study provides the basis for developing transposon and recombinase based tools for genetic engineering of the swine genome.</p

What We Mean When We Talk About Adherence In Respiratory Medicine

The Respiratory Effectiveness Group (REG; www.effectivenessevaluation.org) supported the Expert Adherence Panel Meeting at which many of the concepts presented in this paper were first discussed. REG also supported the manuscript submission costs. ALD, EvG, and MdB have received funding from the European Community's 7th Framework (FP7/2007-2013) under grant agreement no. 282593. Teva supported the meeting costs at which the concepts in this paper were discussed by the co-authors and the open access publication fee for this article. The authors had full editorial control over the ideas presented.Peer reviewedPublisher PD

Record statistics and persistence for a random walk with a drift

We study the statistics of records of a one-dimensional random walk of n steps, starting from the origin, and in presence of a constant bias c. At each time-step the walker makes a random jump of length \eta drawn from a continuous distribution f(\eta) which is symmetric around a constant drift c. We focus in particular on the case were f(\eta) is a symmetric stable law with a L\'evy index 0 < \mu \leq 2. The record statistics depends crucially on the persistence probability which, as we show here, exhibits different behaviors depending on the sign of c and the value of the parameter \mu. Hence, in the limit of a large number of steps n, the record statistics is sensitive to these parameters (c and \mu) of the jump distribution. We compute the asymptotic mean record number after n steps as well as its full distribution P(R,n). We also compute the statistics of the ages of the longest and the shortest lasting record. Our exact computations show the existence of five distinct regions in the (c, 0 < \mu \leq 2) strip where these quantities display qualitatively different behaviors. We also present numerical simulation results that verify our analytical predictions.Comment: 51 pages, 22 figures. Published version (typos have been corrected

Scale-invariance in gravity and implications for the cosmological constant

Recently a scale invariant theory of gravity was constructed by imposing a conformal symmetry on general relativity. The imposition of this symmetry changed the configuration space from superspace - the space of all Riemannian 3-metrics modulo diffeomorphisms - to conformal superspace - the space of all Riemannian 3-metrics modulo diffeomorphisms and conformal transformations. However, despite numerous attractive features, the theory suffers from at least one major problem: the volume of the universe is no longer a dynamical variable. In attempting to resolve this problem a new theory is found which has several surprising and atractive features from both quantisation and cosmological perspectives. Furthermore, it is an extremely restrictive theory and thus may provide testable predictions quickly and easily. One particularly interesting feature of the theory is the resolution of the cosmological constant problem.Comment: Replaced with final version: minor changes to text; references adde

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.

BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type cohorts.Patients and methodsEligible patients had Child-Pugh A liver function and ≤1 prior systemic anticancer regimen, completed ≥4 weeks before study entry. The cabozantinib starting dose was 100 mg daily. After an initial 12-week cabozantinib treatment period, patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 were randomized to cabozantinib or placebo. The primary endpoint of the lead-in stage was objective response rate (ORR) at week 12, and the primary endpoint of the randomized stage was progression-free survival (PFS).ResultsAmong the 41 HCC patients enrolled, the week 12 ORR was 5%, with 2 patients achieving a confirmed partial response (PR). The week 12 disease control rate (PR or SD) was 66% (Asian subgroup: 73%). Of patients with ≥1 post-baseline scan, 78% had tumor regression, with no apparent relationship to prior sorafenib therapy. Alpha-fetoprotein (AFP) response (&gt;50% reduction from baseline) occurred in 9 of the 26 (35%) patients with elevated baseline AFP and ≥1 post-baseline measurement. Twenty-two patients with SD at week 12 were randomized. Median PFS after randomization was 2.5 months with cabozantinib and 1.4 months with placebo, although this difference was not statistically significant. Median PFS and overall survival from Day 1 in all patients were 5.2 and 11.5 months, respectively. The most common grade 3/4 adverse events, regardless of attribution, were diarrhea (20%), hand-foot syndrome (15%), and thrombocytopenia (15%). Dose reductions were utilized in 59% of patients.ConclusionsCabozantinib has clinical activity in HCC patients, including objective tumor responses, disease stabilization, and reductions in AFP. Adverse events were managed with dose reductions.Trial registration numberNCT00940225

Genotype x environment interactions in sire evaluation

Part of Ph. D thesis submitted by S.N. Pani ... --P. [4].Digitized 2007 AES MoU.Includes bibliographical references (page [24])